The most common adverse events (AEs) occurring in patients receiving axitinib (all grades) were hypertension, proteinuria, increased alanine transaminase (ALT), increased alkaline phosphatase (ALK-P), and increased bilirubin. This evidence concerns the gene ALK and hypertensive disorder.